Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Restructuring Costs (2022 - 2024)

Akebia Therapeutics (AKBA) has disclosed Restructuring Costs for 3 consecutive years, with $58000.0 as the latest value for Q1 2024.

  • Quarterly Restructuring Costs fell 45.28% to $58000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $58000.0 through Dec 2024, down 67.96% year-over-year, with the annual reading at $58000.0 for FY2024, 67.96% down from the prior year.
  • Restructuring Costs for Q1 2024 was $58000.0 at Akebia Therapeutics, down from $169000.0 in the prior quarter.
  • The five-year high for Restructuring Costs was $14.5 million in Q2 2022, with the low at -$94000.0 in Q2 2023.
  • Average Restructuring Costs over 3 years is $2.3 million, with a median of $169000.0 recorded in 2023.
  • Peak annual rise in Restructuring Costs hit 6.11% in 2023, while the deepest fall reached 100.65% in 2023.
  • Over 3 years, Restructuring Costs stood at $1.2 million in 2022, then tumbled by 86.17% to $169000.0 in 2023, then plummeted by 65.68% to $58000.0 in 2024.
  • According to Business Quant data, Restructuring Costs over the past three periods came in at $58000.0, $169000.0, and -$94000.0 for Q1 2024, Q3 2023, and Q2 2023 respectively.